Cancer chemoprevention by targeting the epigenome

Current Drug Targets

Volumn 12, Issue 13, 2011, Pages 1925-1956

  Huang, Joseph ^a   Plass, Christoph ^a   Gerhäuser, Clarissa ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Chemoprevention; Chemopreventive agents; Chromatin modifications; Differentiation; DNA methylation; DNA methyltransferase (DNMT); Epigenetic; Epigenomic; Histone acetyl transferase (HAT); Histone acetylation; Histone deacetylase (HDAC); Histone methylation; Hypermethylation; Hypomethylation; Polyphenols; Sirtuins

Indexed keywords

3,3' DIINDOLYLMETHANE; 5 AZA 2' DEOXYCYTIDINE; ALPHA TOCOPHEROL; ANACARDIC ACID; APICIDIN; BUTYRIC ACID; CELECOXIB; CURCUMIN; EFLORNITHINE; ELLAGITANNIN; EPIGALLOCATECHIN GALLATE; FOLIC ACID; GENISTEIN; GREEN TEA EXTRACT; ISOFLAVONE; LA 7017; LYCOPENE; MICRORNA; MITHRAMYCIN; NORDIHYDROGUAIARETIC ACID; OMEGA 3 FATTY ACID; PA 177; PARTHENOLIDE; PHENETHYL ISOTHIOCYANATE; RESVERATROL; RETINOIC ACID; SELENIUM; SULFORAPHANE; SULINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; ZEBULARINE;

ADENOMATOUS POLYP; ALLELE; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CARCINOGENESIS; CELL CYCLE ARREST; CHEMOPROPHYLAXIS; COLON CANCER; COLORECTAL CANCER; CPG ISLAND; DNA DAMAGE; DNA METHYLATION; DNA REPLICATION; DNA SEQUENCE; ENDOMETRIUM CANCER; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENE LOCUS; GENE SILENCING; GENOME IMPRINTING; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; INTESTINE CANCER; KIDNEY CANCER; LIVER TOXICITY; LOSS OF FUNCTION MUTATION; LUNG CANCER; MELANOMA; MOUTH CANCER; NONHUMAN; NONSENSE MUTATION; OVARY CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; RNA STABILITY; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS; STOMACH CANCER; ULTRAVIOLET IRRADIATION; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT; X CHROMOSOME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AGENTS; CHEMOPREVENTION; DNA METHYLATION; DNA, NEOPLASM; ENVIRONMENT; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONES; HUMANS; MICRONUTRIENTS; MICRORNAS; NEOPLASMS;

EID: 82055161827     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798184155     Document Type: Review

References (332)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
2. Costello JF, Plass C. Methylation matters. J Med Genet 2001; 38: 285-303.
3. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007; 8: 286-98.
4. Lyon MF. X-chromosome inactivation. Curr Biol 1999; 9: R235-7.
5. Payer B, Lee JT. X chromosome dosage compensation: how mammals keep the balance. Annu Rev Genet 2008; 42: 733-72.
6. Bartolomei MS, Tilghman SM. Genomic imprinting in mammals. Annu Rev Genet 1997; 31: 493-525.
7. Plass C, Soloway PD. DNA methylation, imprinting and cancer. Eur J Hum Genet 2002; 10: 6-16.
8. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. CTCF mediates methylation-sensitive enhancerblocking activity at the H19/Igf2 locus [see comments]. Nature 2000; 405: 486-9.
9. Santos F, Hendrich B, Reik W, Dean W. Dynamic reprogramming of DNA methylation in the early mouse embryo. Dev Biol 2002; 241: 172-82.
10. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998; 58: 5489-94.
11. Maegawa S, Hinkal G, Kim HS, et al. Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res 2010; 20: 332-40.
12. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007; 447: 433-40.
13. Gallou-Kabani C, Vige A, Gross MS, Junien C. Nutri-epigenomics: lifelong remodelling of our epigenomes by nutritional and metabolic factors and beyond. Clin Chem Lab Med 2007; 45: 321-7.
14. Morgan DK, Whitelaw E. The role of epigenetics in mediating environmental effects on phenotype. Nestle Nutr Workshop Ser Pediatr Program 2009; 63: 109-17; discussion 17-9, 259-68.
15. Suter MA, Aagaard-Tillery KM. Environmental influences on epigenetic profiles. Semin Reprod Med 2009; 27: 380-90.
16. van Doorn R, Gruis NA, Willemze R, van der Velden PA, Tensen CP. Aberrant DNA methylation in cutaneous malignancies. Semin Oncol 2005; 32: 479-87.
17. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 2007; 8: 253-62.
18. McGowan PO, Meaney MJ, Szyf M. Diet and the epigenetic (re)programming of phenotypic differences in behavior. Brain Res 2008; 1237: 12-24.
19. Gama-Sosa MA, Slagel VA, Trewyn RW, et al. The 5- methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983; 11: 6883-94.
20. Plass C, Smiraglia DJ. Genome-wide analysis of DNA methylation changes in human malignancies. Curr Top Microbiol Immunol 2006; 310: 179-98.
21. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003; 300: 489-92.
22. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-74.
23. Kopelovich L, Crowell JA, Fay JR. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst 2003; 95: 1747-57.
24. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002; 21: 5462-82.
25. Bastian PJ, Yegnasubramanian S, Palapattu GS, et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 2004; 46: 698-708.
26. Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer 2008; 123: 1-7.
27. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpGisland methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24: 132-38.
28. Huang TH, Perry MR, Laux DE. Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 1999; 8: 459-70.
29. Rauch T, Li H, Wu X, Pfeifer GP. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res 2006; 66: 7939-47.
30. Figueroa ME, Lugthart S, Li Y, et al. DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia. Cancer Cell 2010; 17: 13-27.
31. Dai Z, Popkie AP, Zhu WG, et al. Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene 2004; 23: 3521-9.
32. Rush LJ, Raval A, Funchain P, et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 2004; 64: 2424-33.
33. Fruhwald MC, MS OD, Dai Z, et al. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas--implications for tumor biology and potential clinical utility. Oncogene 2001; 20: 5033-42.
34. Costello JF, Plass C, Cavenee WK. Aberrant methylation of genes in low-grade astrocytomas. Brain Tumor Pathol 2000; 17: 49-56.
35. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009; 462: 315-22.
36. Lister R, Ecker JR. Finding the fifth base: genome-wide sequencing of cytosine methylation. Genome Res 2009; 19: 959-66.
37. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
38. Rodenhiser D, Mann M. Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 2006; 174: 341-8.
39. Myzak MC, Dashwood RH. Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr Drug Targets 2006; 7: 443-52.
40. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
41. Hauser AT, Jung M. Targeting epigenetic mechanisms: potential of natural products in cancer chemoprevention. Planta Med 2008; 74: 1593-601.
42. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008; 9: 206-18.
43. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459-68.
44. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003; 100: 4389-94.
45. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17-31.
46. Ciccone DN, Chen T. Histone lysine methylation in genomic imprinting. Epigenetics 2009; 4: 216-20.
47. Huyen Y, Zgheib O, Ditullio RA, Jr., et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature 2004; 432: 406-11.
48. Dillon SC, Zhang X, Trievel RC, Cheng X. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol 2005; 6: 227.
49. Fingerman IM, Du HN, Briggs SD. Controlling histone methylation via trans-histone pathways. Epigenetics 2008; 3: 237-42.
50. Cloos PA, Christensen J, Agger K, Helin K. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev 2008; 22: 1115-40.
51. Shi Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet 2007; 8: 829-33.
52. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009; 10: 697-708.
53. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 2009; 9: 773-84.
54. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007; 21: 525-30.
55. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228-34.
56. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
57. Davalos V, Esteller M. MicroRNAs and cancer epigenetics: a macrorevolution. Curr Opin Oncol 2010; 22: 35-45.
58. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10: 389-402.
59. Schembri F, Sridhar S, Perdomo C, et al. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc Natl Acad Sci U S A 2009; 106: 2319-24.
60. Nephew KP, Huang TH. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett 2003; 190: 125-33.
61. Fay JR, Crowell JA, Kopelovich L. Targeting epigenetic regulatory mechanisms in cancer chemoprevention. Expert Opin Ther Targets 2005; 9: 315-28.
62. Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR. Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res 2008; 6: 1365-74.
63. Chen SS, Raval A, Johnson AJ, et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2009; 106: 13433-8.
64. Corpet D. http://www.inra.fr/reseau-nacre/sci-memb/corpet/ indexan.html.
65. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995; 81: 197-205.
66. Yoo CB, Chuang JC, Byun HM, et al. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila Pa) 2008; 1: 233-40.
67. Ross SA. Diet and DNA methylation interactions in cancer prevention. Ann N Y Acad Sci 2003; 983: 197-207.
68. Ross SA, Dwyer J, Umar A, et al. Introduction: diet, epigenetic events and cancer prevention. Nutr Rev 2008; 66 Suppl 1: S1-6.
69. Verma M, Maruvada P, Srivastava S. Epigenetics and cancer. Crit Rev Clin Lab Sci 2004; 41: 585-607.
70. Johnson IT, Belshaw NJ. Environment, diet and CpG island methylation: epigenetic signals in gastrointestinal neoplasia. Food Chem Toxicol 2008; 46: 1346-59.
71. Arasaradnam RP, Commane DM, Bradburn D, Mathers JC. A review of dietary factors and its influence on DNA methylation in colorectal carcinogenesis. Epigenetics 2008; 3: 193-8.
72. Molinie B, Georgel P. Genetic and epigenetic regulations of prostate cancer by genistein. Drug News Perspect 2009; 22: 247-54.
73. Choi S-W, Friso S. Nutrients and Epigenetics. Boca Raton: CRC Press; 2009.
74. Gilbert ER, Liu D. Flavonoids influence epigenetic-modifying enzyme activity: structure - function relationships and the therapeutic potential for cancer. Curr Med Chem 2010; 17: 1756-68.
75. Li Y, Tollefsbol TO. Impact on DNA Methylation in Cancer Prevention and Therapy by Bioactive Dietary Components. Curr Med Chem 2010; 17: 2141-51.
76. Davis CD, Ross SA. Evidence for dietary regulation of microRNA expression in cancer cells. Nutr Rev 2008; 66: 477-82.
77. Saini S, Majid S, Dahiya R. Diet, microRNAs and prostate cancer. Pharm Res 2010; 27: 1014-26.
78. Li Y, Kong D, Wang Z, Sarkar FH. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res 2010; 27: 1027-41.
79. Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer 2010; 116: 4670-6.
80. Huang S. Histone methyltransferases, diet nutrients and tumour suppressors. Nat Rev Cancer 2002; 2: 469-76.
81. Lamprecht SA, Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 2003; 3: 601-14.
82. Duthie SJ. Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Metab Dis 2011; 34: 101-9.
83. Kim YI. Folate, colorectal carcinogenesis, and DNA methylation: lessons from animal studies. Environ Mol Mutagen 2004; 44: 10-25.
84. Kim YI. Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility. J Nutr 2005; 135: 2703-9.
85. Stidley CA, Picchi MA, Leng S, et al. Multivitamins, folate, and green vegetables protect against gene promoter methylation in the aerodigestive tract of smokers. Cancer Res 2010; 70: 568-74.
86. Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671-8.
87. Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res 2006; 66: 10843-8.
88. Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 2005; 64: 527-42.
89. Combs GF, Jr., Gray WP. Chemopreventive agents: selenium. Pharmacol Ther 1998; 79: 179-92.
90. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
91. Jung HJ, Seo YR. Current issues of selenium in cancer chemoprevention. Biofactors 2010; 36: 153-8.
92. Fiala ES, Staretz ME, Pandya GA, El-Bayoumy K, Hamilton SR. Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for DNA cytosine methyltransferase and DNA cytosine methylation. Carcinogenesis 1998; 19: 597-604.
93. Davis CD, Uthus EO, Finley JW. Dietary selenium and arsenic affect DNA methylation in vitro in Caco-2 cells and in vivo in rat liver and colon. J Nutr 2000; 130: 2903-9.
94. Davis CD, Uthus EO. Dietary selenite and azadeoxycytidine treatments affect dimethylhydrazine-induced aberrant crypt formation in rat colon and DNA methylation in HT-29 cells. J Nutr 2002; 132: 292-7.
95. Davis CD, Uthus EO. Dietary folate and selenium affect dimethylhydrazine-induced aberrant crypt formation, global DNA methylation and one-carbon metabolism in rats. J Nutr 2003; 133: 2907-14.
96. Xiang N, Zhao R, Song G, Zhong W. Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells. Carcinogenesis 2008; 29: 2175-81.
97. Sarveswaran S, Liroff J, Zhou Z, Nikitin AY, Ghosh J. Selenite triggers rapid transcriptional activation of p53, and p53-mediated apoptosis in prostate cancer cells: Implication for the treatment of early-stage prostate cancer. Int J Oncol 2010; 36: 1419-28.
98. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17: 193-9.
99. Nian H, Bisson WH, Dashwood WM, Pinto JT, Dashwood RH. Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. Carcinogenesis 2009; 30: 1416-23.
100. Niles RM. Biomarker and animal models for assessment of retinoid efficacy in cancer chemoprevention. Acta Pharmacol Sin 2007; 28: 1383-91.
101. Brtko J. Retinoids, rexinoids and their cognate nuclear receptors: character and their role in chemoprevention of selected malignant diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007; 151: 187-94.
102. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002; 41: 41-55.
103. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1: 181-93.
104. Delage B, Dashwood RH. Dietary manipulation of histone structure and function. Annu Rev Nutr 2008; 28: 347-66.
105. Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003; 22: 6489-96.
106. Garzon R, Pichiorri F, Palumbo T, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007; 26: 4148-57.
107. Rossi A, D'Urso OF, Gatto G, et al. Non-coding RNAs change their expression profile after Retinoid induced differentiation of the promyelocytic cell line NB4. BMC Res Notes 2010; 3: 24.
108. Sirchia SM, Ren M, Pili R, et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 2002; 62: 2455-61.
109. Di Croce L, Raker VA, Corsaro M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079-82.
110. Nouzova M, Holtan N, Oshiro MM, et al. Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays. J Pharmacol Exp Ther 2004; 311: 968-81.
111. Liu L, Saldanha SN, Pate MS, Andrews LG, Tollefsbol TO. Epigenetic regulation of human telomerase reverse transcriptase promoter activity during cellular differentiation. Genes Chromosomes Cancer 2004; 41: 26-37.
112. Phipps SM, Love WK, White T, Andrews LG, Tollefsbol TO. Retinoid-induced histone deacetylation inhibits telomerase activity in estrogen receptor-negative breast cancer cells. Anticancer Res 2009; 29: 4959-64.
113. Phipps SM, Love WK, Mott TE, Andrews LG, Tollefsbol TO. Differential expression of epigenetic modulators during human embryonic stem cell differentiation. Mol Biotechnol 2009; 41: 201-7.
114. Tang XH, Albert M, Scognamiglio T, Gudas LJ. A DNA methyltransferase inhibitor and all-trans retinoic acid reduce oral cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Cancer Prev Res (Phila Pa) 2009; 2: 1100-10.
115. Ju J, Picinich SC, Yang Z, et al. Cancer-preventive activities of tocopherols and tocotrienols. Carcinogenesis 2010; 31: 533-42.
116. Nesaretnam K. Multitargeted therapy of cancer by tocotrienols. Cancer Lett 2008; 269: 388-95.
117. Gaedicke S, Zhang X, Schmelzer C, et al. Vitamin E dependent microRNA regulation in rat liver. FEBS Lett 2008; 582: 3542-6.
118. Fischer A, Gaedicke S, Frank J, Doring F, Rimbach G. Dietary vitamin E deficiency does not affect global and specific DNA methylation patterns in rat liver. Br J Nutr 2010; 104: 935-40.
119. Roy CC, Kien CL, Bouthillier L, Levy E. Short-chain fatty acids: ready for prime time? Nutr Clin Pract 2006; 21: 351-66.
120. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104-19.
121. Lupton JR. Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr 2004; 134: 479-82.
122. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977; 268: 462-4.
123. Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978; 14: 105-13.
124. Sealy L, Chalkley R. The effect of sodium butyrate on histone modification. Cell 1978; 14: 115-21.
125. Spurling CC, Suhl JA, Boucher N, Nelson CE, Rosenberg DW, Giardina C. The short chain fatty acid butyrate induces promoter demethylation and reactivation of RARbeta2 in colon cancer cells. Nutr Cancer 2008; 60: 692-702.
126. Worthley DL, Le Leu RK, Whitehall VL, et al. A human, doubleblind, placebo-controlled, crossover trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer. Am J Clin Nutr 2009; 90: 578-86.
127. Chen YJ, Min J, Shang CZ, et al. [MicroRNA differential expression profile during differentiation of embryonic stem cells towards hepatocytes induced by sodium butyrate]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2008; 30: 469-73.
128. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009; 9: 429-39.
129. Fang MZ, Wang Y, Ai N, et al. Tea polyphenol (-)- epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003; 63: 7563-70.
130. Lee WJ, Shim JY, Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol 2005; 68: 1018-30.
131. Pandey M, Shukla S, Gupta S. Promoter demethylation and chromatin remodeling by green tea polyphenols leads to reexpression of GSTP1 in human prostate cancer cells. Int J Cancer 2009.
132. Lee WJ, Zhu BT. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 2006; 27: 269-77.
133. Fang M, Chen D, Yang CS. Dietary polyphenols may affect DNA methylation. J Nutr 2007; 137: 223S-28S.
134. Berletch JB, Liu C, Love WK, Andrews LG, Katiyar SK, Tollefsbol TO. Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. J Cell Biochem 2008; 103: 509-19.
135. Kato K, Long NK, Makita H, et al. Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. Br J Cancer 2008; 99: 647-54.
136. Gao Z, Xu Z, Hung MS, et al. Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells. Anticancer Res 2009; 29: 2025-30.
137. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006; 5: 997-1014.
138. Chuang JC, Yoo CB, Kwan JM, et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5- aza-2'-deoxycytidine. Mol Cancer Ther 2005; 4: 1515-20.
139. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006; 66: 2794-800.
140. Fini L, Selgrad M, Fogliano V, et al. Annurca apple polyphenols have potent demethylating activity and can reactivate silenced tumor suppressor genes in colorectal cancer cells. J Nutr 2007; 137: 2622-8.
141. Gerhauser C. Cancer chemopreventive potential of apples, apple juice, and apple components. Planta Med 2008; 74: 1608-24.
142. Volate SR, Muga SJ, Issa AY, Nitcheva D, Smith T, Wargovich MJ. Epigenetic modulation of the retinoid X receptor alpha by green tea in the azoxymethane-Apc Min/+ mouse model of intestinal cancer. Mol Carcinog 2009; 48: 920-33.
143. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 2001; 98: 10350-5.
144. Caporali A, Davalli P, Astancolle S, et al. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004; 25: 2217-24.
145. Adhami VM, Siddiqui IA, Sarfaraz S, et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res 2009; 15: 1947-53.
146. Yuasa Y, Nagasaki H, Akiyama Y, et al. DNA methylation status is inversely correlated with green tea intake and physical activity in gastric cancer patients. Int J Cancer 2009; 124: 2677-82.
147. Balasubramanian S, Adhikary G, Eckert RL. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Carcinogenesis 2010; 31: 496-503.
148. Tsang WP, Kwok TT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem 2010; 21: 140-6.
149. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 2009; 41: 87-95.
150. Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst 2006; 98: 1275-84.
151. Jian L. Soy, isoflavones, and prostate cancer. Mol Nutr Food Res 2009; 53: 217-26.
152. [Steiner C, Arnould S, Scalbert A, Manach C. Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br J Nutr 2008; 99 E Suppl 1: ES78-108.
153. Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett 2008; 269: 226-42.
154. Helferich WG, Andrade JE, Hoagland MS. Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 2008; 16: 219-26.
155. Taylor CK, Levy RM, Elliott JC, Burnett BP. The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr Rev 2009; 67: 398-415.
156. Warri A, Saarinen NM, Makela S, Hilakivi-Clarke L. The role of early life genistein exposures in modifying breast cancer risk. Br J Cancer 2008; 98: 1485-93.
157. Hilakivi-Clarke L. Nutritional modulation of terminal end buds: its relevance to breast cancer prevention. Curr Cancer Drug Targets 2007; 7: 465-74.
158. Powles TJ. Anti-oestrogenic prevention of breast cancer--the make or break point. Nat Rev Cancer 2002; 2: 787-94.
159. Hong T, Nakagawa T, Pan W, et al. Isoflavones stimulate estrogen receptor-mediated core histone acetylation. Biochem Biophys Res Commun 2004; 317: 259-64.
160. Majid S, Kikuno N, Nelles J, et al. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res 2008; 68: 2736-44.
161. Kikuno N, Shiina H, Urakami S, et al. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer 2008; 123: 552-60.
162. Basak S, Pookot D, Noonan EJ, Dahiya R. Genistein downregulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol Cancer Ther 2008; 7: 3195-202.
163. Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, Yang CS. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 2005; 11: 7033-41.
164. King-Batoon A, Leszczynska JM, Klein CB. Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ Mol Mutagen 2008; 49: 36-45.
165. Vardi A, Bosviel R, Rabiau N, et al. Soy Phytoestrogens Modify DNA Methylation of GSTP1, RASSF1A, EPH2 and BRCA1 Promoter in Prostate Cancer Cells. In vivo 2010; 24: 393-400.
166. Li Y, Liu L, Andrews LG, Tollefsbol TO. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int J Cancer 2009; 125: 286-96.
167. Majid S, Dar AA, Ahmad AE, et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 2009; 30: 662-70.
168. Majid S, Dar AA, Shahryari V, et al. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer 2010; 116: 66-76.
169. Parker LP, Taylor DD, Kesterson J, Metzinger DS, Gercel-Taylor C. Modulation of microRNA associated with ovarian cancer cells by genistein. Eur J Gynaecol Oncol 2009; 30: 616-21.
170. Li Y, VandenBoom TG, 2nd, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-tomesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-12.
171. Majid S, Dar AA, Saini S, et al. Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. Cancer Res 2010; 70: 2809-18.
172. Sun Q, Cong R, Yan H, et al. Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression. Oncol Rep 2009; 22: 563-7.
173. Day JK, Bauer AM, DesBordes C, et al. Genistein alters methylation patterns in mice. J Nutr 2002; 132: 2419S-23S.
174. Dolinoy DC, Weidman JR, Waterland RA, Jirtle RL. Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. Environ Health Perspect 2006; 114: 567-72.
175. Guerrero-Bosagna CM, Sabat P, Valdovinos FS, Valladares LE, Clark SJ. Epigenetic and phenotypic changes result from a continuous pre and post natal dietary exposure to phytoestrogens in an experimental population of mice. BMC Physiol 2008; 8: 17.
176. Tang WY, Newbold R, Mardilovich K, et al. Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology 2008; 149: 5922-31.
177. Qin W, Zhu W, Shi H, et al. Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women. Nutr Cancer 2009; 61: 238-44.
178. Liu Z, Liu S, Xie Z, et al. Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J Pharmacol Exp Ther 2009; 329: 505-14.
179. Pajak B, Gajkowska B, Orzechowski A. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem Cytobiol 2008; 46: 129-35.
180. Surh YJ, Chun KS. Cancer chemopreventive effects of curcumin. Adv Exp Med Biol 2007; 595: 149-72.
181. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199-225.
182. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J2009; 11: 495-510.
183. Patel BB, Majumdar AP. Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. Nutr Cancer 2009; 61: 842-6.
184. Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004; 279: 51163-71.
185. Kang J, Chen J, Shi Y, Jia J, Zhang Y. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. Biochem Pharmacol 2005; 69: 1205-13.
186. Chen Y, Shu W, Chen W, Wu Q, Liu H, Cui G. Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin Pharmacol Toxicol 2007; 101: 427-33.
187. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995; 270: 24995-5000.
188. Liu Z, Xie Z, Jones W, et al. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett 2009; 19: 706-9.
189. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Therap 2008; 7: 464-73.
190. Ali S, Ahmad A, Banerjee S, et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70: 3606-17.
191. Zhang J, Zhang T, Ti X, et al. Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochem Biophys Res Commun 2010; 399: 1-6.
192. Okuda T, Yoshida T, Hatano T. Ellagitannins as active constituents of medicinal plants. Planta Med 1989; 55: 117-22.
193. Wen XY, Wu SY, Li ZQ, et al. Ellagitannin (BJA3121), an antiproliferative natural polyphenol compound, can regulate the expression of MiRNAs in HepG2 cancer cells. Phytother Res 2009; 23: 778-84.
194. Verkerk R, Schreiner M, Krumbein A, et al. Glucosinolates in Brassica vegetables: the influence of the food supply chain on intake, bioavailability and human health. Mol Nutr Food Res 2009; 53 Suppl 2: S219.
195. Safe S, Papineni S, Chintharlapalli S. Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs. Cancer Lett 2008; 269: 326-38.
196. Pappa G, Lichtenberg M, Iori R, Barillari J, Bartsch H, Gerhauser C. Comparison of growth inhibition profiles and mechanisms of apoptosis induction in human colon cancer cell lines by isothiocyanates and indoles from Brassicaceae. Mutat Res 2006; 599: 76-87.
197. Li Y, Vandenboom TG, 2nd, Wang Z, et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010; 70: 1486-95.
198. Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM, De Flora S. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J 2009; 23: 806-12.
199. Bhattacharya K, Samanta SK, Tripathi R, et al. Apoptotic effects of mahanine on human leukemic cells are mediated through crosstalk between Apo-1/Fas signaling and the Bid protein and via mitochondrial pathways. Biochem Pharmacol 2010; 79: 361-72.
200. Sheikh KD, Banerjee PP, Jagadeesh S, et al. Fluorescent epigenetic small molecule induces expression of the tumor suppressor rasassociation domain family 1A and inhibits human prostate xenograft. J Med Chem 2010; 53: 2376-82.
201. Beaulieu N, Morin S, Chute IC, Robert MF, Nguyen H, MacLeod AR. An essential role for DNA methyltransferase DNMT3B in cancer cell survival. J Biol Chem 2002; 277: 28176-81.
202. Blecha JE, Anderson MO, Chow JM, et al. Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs. Bioorg Med Chem Lett 2007; 17: 4026-9.
203. [Lu JM, Nurko J, Weakley SM, et al. Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update. Med Sci Monit 2010; 16: RA93-100.
204. Ryan CJ, Harzstark AH, Rosenberg J, et al. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int 2008; 101: 436-9.
205. Cui Y, Lu C, Liu L, et al. Reactivation of methylation-silenced tumor suppressor gene p16INK4a by nordihydroguaiaretic acid and its implication in G1 cell cycle arrest. Life Sci 2008; 82: 247-55.
206. Cui Y, Lu C, Kang A, et al. Nordihydroguaiaretic acid restores expression of silenced E-cadherin gene in human breast cancer cell lines and xenografts. Anticancer Drugs 2008; 19: 487-94.
207. Byun HM, Choi SH, Laird PW, et al. 2'-Deoxy-N4-[2-(4- nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. Cancer Lett 2008; 266: 238-48.
208. van Breemen RB, Pajkovic N. Multitargeted therapy of cancer by lycopene. Cancer Lett 2008; 269: 339-51.
209. Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 2007; 64: 1105-27.
210. Zhang Y, Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta Pharmacol Sin 2007; 28: 1343-54.
211. Clarke JD, Dashwood RH, Ho E. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 2008; 269: 291-304.
212. Hecht SS. Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev 2000; 32: 395-411.
213. Cheung KL, Kong AN. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J 2010; 12: 87-97.
214. Nishikawa T, Tsuno NH, Okaji Y, et al. Inhibition of autophagy potentiates sulforaphane-induced apoptosis in human colon cancer cells. Ann Surg Oncol 2010; 17: 592-602.
215. Herman-Antosiewicz A, Johnson DE, Singh SV. Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells. Cancer Res 2006; 66: 5828-35.
216. Xiao D, Singh SV. Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo. Cancer Res 2007; 67: 2239-46.
217. Bommareddy A, Hahm ER, Xiao D, et al. Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res 2009; 69: 3704-12.
218. Trachootham D, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006; 10: 241-52.
219. [http://www.cancer.gov/clinicaltrials.
220. Nian H, Delage B, Ho E, Dashwood RH. Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen 2009; 50: 213-21.
221. Myzak MC, Karplus PA, Chung FL, Dashwood RH. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 2004; 64: 5767-74.
222. Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis 2006; 27: 811-9.
223. Pledgie-Tracy A, Sobolewski MD, Davidson NE. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther 2007; 6: 1013-21.
224. Gibbs A, Schwartzman J, Deng V, Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A 2009; 106: 16663-8.
225. Meeran SM, Patel SN, Tollefsbol TO. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One 2010; 5: e11457.
226. Dashwood RH, Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 2007; 17: 363-9.
227. Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J 2006; 20: 506-8.
228. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) 2007; 232: 227-34.
229. Wang LG, Beklemisheva A, Liu XM, Ferrari AC, Feng J, Chiao JW. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol Carcinog 2007; 46: 24-31.
230. Wang LG, Liu XM, Fang Y, et al. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 2008; 33: 375-80.
231. Wang LG, Chiao JW. Prostate cancer chemopreventive activity of phenethyl isothiocyanate through epigenetic regulation (Review). Int J Oncol 2010; 37: 533-9.
232. Izzotti A, Calin GA, Steele VE, et al. Chemoprevention of cigarette smoke-induced alterations of MicroRNA expression in rat lungs. Cancer Prev Res (Phila Pa) 2010; 3: 62-72.
233. Izzotti A, Larghero P, Cartiglia C, et al. Modulation of microRNA expression by budesonide, phenethyl isothiocyanate, and cigarette smoke in mouse liver and lung. Carcinogenesis 2010; 31: 894-901.
234. Lu Q, Lin X, Feng J, et al. Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol 2008; 1: 6.
235. Beklemisheva AA, Fang Y, Feng J, Ma X, Dai W, Chiao JW. Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res 2006; 26: 1225-30.
236. Ma X, Fang Y, Beklemisheva A, et al. Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol 2006; 28: 1287-93.
237. Huang YQ, Ma XD, Zhen RJ, Chiao JW, Liu DL. [Experiment study of PHI on histone methylation and acetylation in Molt-4 cells]. Zhonghua Xue Ye Xue Za Zhi 2007; 28: 612-5.
238. Xiao L, Huang Y, Zhen R, Chiao JW, Liu D, Ma X. Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate. Acta Haematol 2010; 123: 71-6.
239. Huang YQ, Ma XD, Lai YD, Wang XZ, Chiao JW, Liu DL. [Phenylhexyl isothiocyanate(PHI) regulates histone methylation and acetylation and induces apoptosis in SMMC-7721 cells]. Zhonghua Gan Zang Bing Za Zhi 2010; 18: 209-12.
240. Bianchini F, Vainio H. Allium vegetables and organosulfur compounds: do they help prevent cancer? Environ Health Perspect 2001; 109: 893-902.
241. Powolny AA, Singh SV. Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer Lett 2008; 269: 305-14.
242. Lea MA, Rasheed M, Randolph VM, Khan F, Shareef A, desBordes C. Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine. Nutr Cancer 2002; 43: 90-102.
243. Nian H, Delage B, Pinto JT, Dashwood RH. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis 2008; 29: 1816-24.
244. Druesne-Pecollo N, Chaumontet C, Latino-Martel P. Diallyl disulfide increases histone acetylation in colon cells in vitro and in vivo. Nutr Rev 2008; 66 Suppl 1: S39-41.
245. Druesne-Pecollo N, Chaumontet C, Pagniez A, et al. In vivo treatment by diallyl disulfide increases histone acetylation in rat colonocytes. Biochem Biophys Res Commun 2007; 354: 140-7.
246. Lombo F, Menendez N, Salas JA, Mendez C. The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives. Appl Microbiol Biotechnol 2006; 73: 1-14.
247. Lin RK, Hsu CH, Wang YC. Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells. Anticancer Drugs 2007; 18: 1157-64.
248. Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R. Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression. BMB Rep 2009; 42: 493-9.
249. Han JW, Ahn SH, Park SH, et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 2000; 60: 6068-74.
250. You JS, Kang JK, Lee EK, et al. Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene 2008; 27: 1376-86.
251. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-40.
252. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11-21.
253. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009; 17: 55-67.
254. Gerner EW, Meyskens FL, Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004; 4: 781-92.
255. Meyskens FL, Jr., Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999; 5: 945-51.
256. Meyskens FL, Jr., McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa) 2008; 1: 32-8.
257. Pereira MA, Tao L, Wang W, et al. Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. Carcinogenesis 2004; 25: 1917-23.
258. Tao L, Wang W, Kramer PM, Lubet RA, Steele VE, Pereira MA. Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer. Mol Carcinog 2004; 39: 79-84.
259. Oki Y, Aoki E, Issa JP. Decitabine--bedside to bench. Crit Rev Oncol Hematol 2007; 61: 140-52.
260. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005; 97: 1498-506.
261. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins--novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 2008; 7: 841-53.
262. Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 2009; 9: 123-8.
263. Holloway KR, Calhoun TN, Saxena M, et al. SIRT1 regulates Dishevelled proteins and promotes transient and constitutive Wnt signaling. Proc Natl Acad Sci U S A 2010; 107: 9216-21.
264. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-6.
265. Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390-2.
266. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-20.
267. Pezzuto JM. Resveratrol as an inhibitor of carcinogenensis. Pharm Biol 2008; 46: 443-573.
268. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 2008; 269: 243-61.
269. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
270. Tili E, Michaille JJ, Alder H, et al. Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFbeta signaling pathway in SW480 cells. Biochem Pharmacol 2010; 80: 2057-65.
271. Tili E, Michaille JJ, Adair B, et al. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 2010; 31: 1561-66.
272. Olaharski AJ, Rine J, Marshall BL, et al. The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases. PLoS Genet 2005; 1: e77.
273. Heltweg B, Gatbonton T, Schuler AD, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006; 66: 4368-77.
274. Varier RA, Swaminathan V, Balasubramanyam K, Kundu TK. Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy. Biochem Pharmacol 2004; 68: 1215-20.
275. Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. Small molecule modulators of histone acetyltransferase p300. J Biol Chem 2003; 278: 19134-40.
276. Sun Y, Jiang X, Chen S, Price BD. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett 2006; 580: 4353-6.
277. Sung B, Pandey MK, Ahn KS, et al. Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factorkappaBalpha kinase, leading to potentiation of apoptosis. Blood 2008; 111: 4880-91.
278. Padhye S, Ahmad A, Oswal N, Sarkar FH. Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs. J Hematol Oncol 2009; 2: 38.
279. Balasubramanyam K, Altaf M, Varier RA, et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 2004; 279: 33716-26.
280. Prasad S, Ravindran J, Sung B, Pandey MK, Aggarwal BB. Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther 2010; 9: 856-68.
281. [Serfaty L, Bissonnette M, Poupon R. Ursodeoxycholic acid and chemoprevention of colorectal cancer. Gastroenterol Clin Biol.
282. Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 2009; 50: 1721-34.
283. Akare S, Jean-Louis S, Chen W, Wood DJ, Powell AA, Martinez JD. Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. Int J Cancer 2006; 119: 2958-69.
284. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009; 8: 1409-20.
285. Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 2007; 109: 2579-88.
286. Cherrier T, Suzanne S, Redel L, et al. p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1. Oncogene 2009; 28: 3380-9.
287. Lakshmikuttyamma A, Scott SA, DeCoteau JF, Geyer CR. Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene 2010; 29: 576-88.
288. Huang Y, Stewart TM, Wu Y, et al. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res 2009; 15: 7217-28.
289. Huang Y, Greene E, Murray Stewart T, et al. Inhibition of lysinespecific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A 2007; 104: 8023-8.
290. Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 2008; 269: 363-77.
291. Dimri M, Bommi P, Sahasrabuddhe AA, Khandekar JD, Dimri GP. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Carcinogenesis 2010; 31: 489-95.
292. Davidson LA, Wang N, Shah MS, Lupton JR, Ivanov I, Chapkin RS. n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis 2009; 30: 2077-84.
293. Love WK, Berletch JB, Andrews LG, Tollefsbol TO. Epigenetic regulation of telomerase in retinoid-induced differentiation of human leukemia cells. Int J Oncol 2008; 32: 625-31.
294. Wu JT, Archer SY, Hinnebusch B, Meng S, Hodin RA. Transient vs. prolonged histone hyperacetylation: effects on colon cancer cell growth, differentiation, and apoptosis. Am J Physiol Gastrointest Liver Physiol 2001; 280: G482-90.
295. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004; 23: 6261-71.
296. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66: 1277-81.
297. Morey Kinney SR, Zhang W, Pascual M, et al. Lack of evidence for green tea polyphenols as DNA methylation inhibitors in murine prostate. Cancer Prev Res (Phila Pa) 2009; 2: 1065-75.
298. Paluszczak J, Krajka-Kuzniak V, Baer-Dubowska W. The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol Lett 2010; 192: 119-25.
299. Jawaid K, Crane SR, Nowers JL, Lacey M, Whitehead SA. Longterm genistein treatment of MCF-7 cells decreases acetylated histone 3 expression and alters growth responses to mitogens and histone deacetylase inhibitors. J Steroid Biochem Mol Biol 2010; 120: 164-71.
300. Jagadeesh S, Sinha S, Pal BC, Bhattacharya S, Banerjee PP. Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells. Biochem Biophys Res Commun 2007; 362: 212-7.
301. Lantry LE, Zhang Z, Crist KA, et al. 5-Aza-2'-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1- butanone-induced primary mouse lung tumor model. Carcinogenesis 1999; 20: 343-6.
302. Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003; 63: 7089-93.
303. McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ, Day ML. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 2006; 66: 385-92.
304. Hellebrekers DM, Jair KW, Vire E, et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 2006; 5: 467-75.
305. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 2005; 1: 143-5.
306. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-66.
307. Mass MJ, Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 1997; 386: 263-77.
308. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93: 9821-6.
309. Aggerholm A, Guldberg P, Hokland M, Hokland P. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res 1999; 59: 436-41.
310. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a highthroughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28: E32.
311. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997; 25: 2532-4.
312. Brena RM, Auer H, Kornacker K, Plass C. Quantification of DNA methylation in electrofluidics chips (Bio-COBRA). Nat Protoc 2006; 1: 52-8.
313. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5- methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992; 89: 1827-31.
314. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007; 2: 2265-75.
315. Gonzalgo ML, Jones PA. Quantitative methylation analysis using methylation-sensitive single-nucleotide primer extension (Ms- SNuPE). Methods 2002; 27: 128-33.
316. Oeth P, del Mistro G, Marnellos G, Shi T, van den Boom D. Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY). Methods Mol Biol 2009; 578: 307-43.
317. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative highthroughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 2005; 102: 15785-90.
318. Schilling E, Rehli M. Global, comparative analysis of tissuespecific promoter CpG methylation. Genomics 2007; 90: 314-23.
319. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39: 457-66.
320. Khulan B, Thompson RF, Ye K, et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res 2006; 16: 1046-55.
321. Huang TH, Laux DE, Hamlin BC, Tran P, Tran H, Lubahn DB. Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. Cancer Res 1997; 57: 1030-4.
322. Ho SM, Tang WY. Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases. Reprod Toxicol 2007; 23: 267-82.
323. Yan PS, Chen CM, Shi H, Rahmatpanah F, Wei SH, Huang TH. Applications of CpG island microarrays for high-throughput analysis of DNA methylation. J Nutr 2002; 132: 2430S-34S.
324. Shechter D, Dormann HL, Allis CD, Hake SB. Extraction, purification and analysis of histones. Nat Protoc 2007; 2: 1445-57.
325. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005; 280: 17187-95.
326. Kwon HJ, Owa T, Hassig CA, Shimada J, Schreiber SL. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci U S A 1998; 95: 3356-61.
327. Lau OD, Kundu TK, Soccio RE, et al. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 2000; 5: 589-95.
328. Wang H, Cao R, Xia L, et al. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol Cell 2001; 8: 1207-17.
329. Zhang X, Guo C, Chen Y, et al. Epitope tagging of endogenous proteins for genome-wide ChIP-chip studies. Nat Methods 2008; 5: 163-5.
330. Valouev A, Johnson DS, Sundquist A, et al. Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data. Nat Methods 2008; 5: 829-34.
331. Carroll JS, Liu XS, Brodsky AS, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005; 122: 33-43.
332. Sargeant AM, Rengel RC, Kulp SK, et al. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008; 68: 3999-4009.